NASDAQ:HPTX - Horizon Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$45.99 0.00 (0.00 %)
(As of 05/22/2018 03:53 PM ET)
Previous Close$45.99
Today's RangeN/A
52-Week Range$20.23 - $46.96
VolumeN/A
Average Volume786,899 shs
Market Capitalization$964.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics logoHorizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive HPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins23.13%
Return on Equity21.30%
Return on Assets15.42%

Miscellaneous

EmployeesN/A
Outstanding Shares20,980,000

Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics Inc (NASDAQ:HPTX) announced its quarterly earnings results on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to analysts' expectations of $24.60 million. Horizon Therapeutics had a net margin of 23.13% and a return on equity of 21.30%. The company's revenue was up 65.6% on a year-over-year basis. View Horizon Therapeutics' Earnings History.

Has Horizon Therapeutics been receiving favorable news coverage?

Headlines about HPTX stock have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Horizon Therapeutics earned a news sentiment score of 0.06 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.27 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Horizon Therapeutics?

Shares of HPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of HPTX stock can currently be purchased for approximately $45.99.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $964.29 million.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.


MarketBeat Community Rating for Horizon Therapeutics (HPTX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Horizon Therapeutics (NASDAQ:HPTX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/22/2016 forward)

Earnings

Horizon Therapeutics (NASDAQ:HPTX) Earnings History and Estimates Chart

Earnings by Quarter for Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics (NASDAQ HPTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2015Q414($0.20)$0.47$24.60 million$30.80 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.05)($0.06)$24.74 million$26.20 millionViewN/AView Earnings Details
8/7/2014Q2($0.18)$0.89$22.00 million$37.10 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.01)$0.12$17.00 million$19.48 millionViewN/AView Earnings Details
2/27/2014Q4 2013$0.03$0.13$15.75 million$18.63 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.08)$0.10$12.60 million$15.49 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.17)($0.22)$2.17 million$7.30 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.67)($0.52)$0.50 million$0.78 millionViewN/AView Earnings Details
2/25/2013Q412($0.38)($0.50)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.56)$0.44ViewN/AView Earnings Details
9/6/2012Q2 2012($10.14)($15.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Horizon Therapeutics (NASDAQ:HPTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Horizon Therapeutics (NASDAQ HPTX) Insider Trading and Institutional Ownership History

Insider Trading History for Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics (NASDAQ HPTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2015Christine A NashSVPSell10,000$37.56$375,600.00View SEC Filing  
3/10/2015Christine A NashSVPSell9,900$29.63$293,337.00View SEC Filing  
1/20/2015Christine A NashSVPSell5,000$24.82$124,100.00View SEC Filing  
6/6/2014Scott D SandellMajor ShareholderSell1,430$5.54$7,922.20View SEC Filing  
3/4/2014James HealyDirectorSell23,625$30.02$709,222.50View SEC Filing  
1/14/2014Christine NashSVPSell10,000$24.09$240,900.005,098View SEC Filing  
9/20/2013Highland Management Partners Vmajor shareholderSell5,754$25.84$148,683.36View SEC Filing  
9/18/2013Highland Management Partners Vmajor shareholderSell15,544$26.00$404,144.00View SEC Filing  
9/16/2013Highland Management Partners Vmajor shareholderSell8,300$26.29$218,207.00View SEC Filing  
9/11/2013Highland Management Partners VMajor ShareholderSell34,573$26.56$918,258.88View SEC Filing  
9/9/2013Highland Management Partners VMajor ShareholderSell18,048$26.06$470,330.88View SEC Filing  
8/5/2013Highland Management Partners Vmajor shareholderSell25,000$25.48$637,000.00View SEC Filing  
8/2/2013Highland Management Partners VMajor ShareholderSell47,245$25.35$1,197,660.75View SEC Filing  
5/30/2013Bay City Capital LlcMajor ShareholderSell17,366$21.06$365,727.96View SEC Filing  
5/20/2013Bay City Capital LlcMajor ShareholderSell131,455$22.68$2,981,399.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Horizon Therapeutics (NASDAQ HPTX) News Headlines

Source:
DateHeadline
Why Global Blood Therapeutics (GBT) Could Be Positioned for a SlumpWhy Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
www.msn.com - March 21 at 11:53 AM
Kalvista Pharmaceuticals (KALV) & Horizon Therapeutics (HPTX) Head to Head ContrastKalvista Pharmaceuticals (KALV) & Horizon Therapeutics (HPTX) Head to Head Contrast
www.americanbankingnews.com - March 14 at 2:06 PM
Horizon Therapeutics (HPTX) & Its Competitors Head-To-Head SurveyHorizon Therapeutics (HPTX) & Its Competitors Head-To-Head Survey
www.americanbankingnews.com - January 24 at 9:12 AM
Contrasting Horizon Therapeutics (HPTX) & Its CompetitorsContrasting Horizon Therapeutics (HPTX) & Its Competitors
www.americanbankingnews.com - January 20 at 7:12 AM
Critical Analysis: Horizon Therapeutics (HPTX) vs. Its RivalsCritical Analysis: Horizon Therapeutics (HPTX) vs. Its Rivals
www.americanbankingnews.com - January 19 at 5:28 AM
Reviewing Horizon Therapeutics (HPTX) and Its PeersReviewing Horizon Therapeutics (HPTX) and Its Peers
www.americanbankingnews.com - January 17 at 11:10 PM
Horizon Therapeutics (HPTX) vs. Its Rivals Critical ComparisonHorizon Therapeutics (HPTX) vs. Its Rivals Critical Comparison
www.americanbankingnews.com - January 16 at 7:56 PM
Reviewing Horizon Therapeutics (HPTX) and Peregrine Pharmaceuticals (CDMO)Reviewing Horizon Therapeutics (HPTX) and Peregrine Pharmaceuticals (CDMO)
www.americanbankingnews.com - January 13 at 11:34 PM
Horizon Therapeutics (HPTX) & Its Competitors Critical ReviewHorizon Therapeutics (HPTX) & Its Competitors Critical Review
www.americanbankingnews.com - January 12 at 7:04 PM
Contrasting Horizon Therapeutics (HPTX) and Its CompetitorsContrasting Horizon Therapeutics (HPTX) and Its Competitors
www.americanbankingnews.com - January 12 at 3:28 PM
Horizon Therapeutics (HPTX) versus The Competition Financial ContrastHorizon Therapeutics (HPTX) versus The Competition Financial Contrast
www.americanbankingnews.com - January 9 at 5:10 AM
Horizon Therapeutics (HPTX) and Its Rivals Financial ContrastHorizon Therapeutics (HPTX) and Its Rivals Financial Contrast
www.americanbankingnews.com - January 6 at 11:36 PM
Head to Head Analysis: Horizon Therapeutics (HPTX) and The CompetitionHead to Head Analysis: Horizon Therapeutics (HPTX) and The Competition
www.americanbankingnews.com - January 4 at 5:12 AM
Horizon Therapeutics (HPTX) and Its Peers Head-To-Head AnalysisHorizon Therapeutics (HPTX) and Its Peers Head-To-Head Analysis
www.americanbankingnews.com - January 3 at 5:36 PM
Reviewing Horizon Therapeutics (HPTX) & Its PeersReviewing Horizon Therapeutics (HPTX) & Its Peers
www.americanbankingnews.com - January 3 at 12:30 PM
Horizon Therapeutics (HPTX) versus Its Rivals Financial ContrastHorizon Therapeutics (HPTX) versus Its Rivals Financial Contrast
www.americanbankingnews.com - January 3 at 3:12 AM
Head-To-Head Analysis: Horizon Therapeutics (HPTX) versus Its CompetitorsHead-To-Head Analysis: Horizon Therapeutics (HPTX) versus Its Competitors
www.americanbankingnews.com - December 31 at 9:30 AM
Horizon Therapeutics (HPTX) and The Competition Head to Head ContrastHorizon Therapeutics (HPTX) and The Competition Head to Head Contrast
www.americanbankingnews.com - December 28 at 3:21 AM
Comparing Synlogic (SYBX) & Horizon Therapeutics (HPTX)Comparing Synlogic (SYBX) & Horizon Therapeutics (HPTX)
www.americanbankingnews.com - December 26 at 1:34 PM
Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture StudyPluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration - a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
globenewswire.com - November 22 at 8:28 PM
Horizon Therapeutics (HPTX) & Ocera Therapeutics (OCRX) Head-To-Head ContrastHorizon Therapeutics (HPTX) & Ocera Therapeutics (OCRX) Head-To-Head Contrast
www.americanbankingnews.com - November 22 at 8:04 AM
United Therapeutics gets much-needed reprieve with drug patentUnited Therapeutics gets much-needed reprieve with drug patent
www.bizjournals.com - November 21 at 7:40 PM
Critical Comparison: Catalyst Biosciences (CBIO) & Horizon Therapeutics (HPTX)Critical Comparison: Catalyst Biosciences (CBIO) & Horizon Therapeutics (HPTX)
www.americanbankingnews.com - October 20 at 12:32 AM
Analyzing Horizon Therapeutics (HPTX) and Biogen (BIIB)Analyzing Horizon Therapeutics (HPTX) and Biogen (BIIB)
www.americanbankingnews.com - September 28 at 8:48 AM
Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017
globenewswire.com - July 10 at 7:31 PM
HYPERION THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of DelistingHYPERION THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting
biz.yahoo.com - May 7 at 4:04 PM
HYPERION THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportHYPERION THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 6 at 4:12 PM
Horizon Pharma buying Hyperion for about $1.1 billionHorizon Pharma buying Hyperion for about $1.1 billion
www.latimes.com - March 30 at 6:52 PM

SEC Filings

Horizon Therapeutics (NASDAQ:HPTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Horizon Therapeutics (NASDAQ:HPTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Horizon Therapeutics (NASDAQ HPTX) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.